Short Communication - Journal of Public Health Policy and Planning (2021) Volume 5, Issue 3

Management guidelines for age group above 50 yrs with covid-19

Ibrahim Almasi^*

*Department of Epidemiology and Public Health, Alfaisal University, Riyadh, Saudi Arabia

Corresponding Author:

Ibrahim Almasi
Department of Epidemiology and Public Health
Alfaisal University
Riyadh, Saudi Arabia
E-mail: almasi@alfaisal.edu

Accepted date: March 18, 2021

Short Communication

Countries with higher population living in urban areas, with lower reduction in mobility at the beginning of the pandemic, and borders having more infected people experienced higher peak of COVID-19 deaths. It is very difficult to for bigger population size and whereas a high number of foreign travelers could accelerate it.

According to researchers are defined as in future COVID-19 is a more severe illness than seasonal influenza. It is more pandemic stated by public health professionals and evidence-based advocacy is part of the response to COVID-19 to control dangerous corona virus which is uncontrolled public health control measures. The corona virus can also spread rapidly after other people may become contact with infected people by touching with used materials sneeze, cough on, or touch surfaces, or objects, such as tables, doorknobs and handrails [1].

The lungs and liver may damage by corona virus as demonstrated by previous research done by scientists. Once the infection starts it effects on the immune responses by releasing the inflammatory mediators like chemokines and cytokines. Some results outcome showed the inflammatory biomarkers like CRP and IL-6, by 75% and 54%respectively, indicating the host responses to inflammation that caused by SARS-CoV-2. In addition, the high body temperature in the patients is due to the cytokines storm [2,3]. It is worthy to mention that IL-6 is one of the biomarker for sepsis and septic lung injury. Notably, our results showed that most of patients had markedly high IL-6. Nearly, two third of patients were symptomatic and one third of the patients in our study were asymptomatic, and it has been shown that asymptomatic carriers are a potential risk factor for transition of SARS-CoV-2 which may delay controlling this virus.

Presently vaccines are developed from different companies with mild changes. People who inject drugs are potentially more immunity to respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and coronavirus disease 2019 (COVID-19) than other a high level of underlying health conditions and lifestyle risk factors like Blood pressure and Diabetes. However, researchers are extent there studies on covid-19 to which strain is affected by the pandemic is limited. Remarkably high rate of pandemic is observed in poor developed countries [4]. Symptoms and clinical manifestations are different from strain to strings and rather few problems in the five dimensions investigated. Presently, study findings particularly genes related with virus and the link between different strains of covid-19.

In 2020 a new coronavirus strain has been identified and many instructions have been directed towards the development of effective vaccines. The developments for vaccination is totally based on the several factors are considered. Among that the genome structure is very important to prepare the vaccine [5]. Presently, the aim of experts is to analyze the theme of vaccine during at the stage of COVID-19 pandemic, with specifically focus on vaccine toward COVID-19 vaccine.

Safety instructions and measurements should follow every person and needs have changed due to the effect of COVID-19. Especially for aged people and who is having lifelong existence diseases should take care of their health and follow the instructions given by medical experts and safety planning mobile application for use during COVID-19 and future public health emergencies.

References

1. Abeer K. Principles and effectiveness of microbiological containment measures in COVID-19 pandemic induced by SARS-CoV-2. Biomed Res. 2021; S36-S42.
2. Mohammed M. Evaluation of hepatic enzymes activities in COVID-19 patients in Kurdistan region of Iraq. Biomed Res. 2021; S24-S27.
3. Thomas J. Obesity a Major Risk for Covid 19 Patients. J Obes Weight Loss Ther.2020;10:404.
4. Suhasini S. COVID-19: Pathogenesis and Complications. J Comm Pub Health Nursing.2021 7:26.
5. Alaba OEG, Eric EU, Avwioro GO, et al. The Role of Histopathology Laboratory in Post-Mortem Examination of COVID-19 Cases: Challenges and Way Forward. Diagn Pathol Open.2020;S1:003.